期刊文献+

三种不同血液净化方式对维持性血液透析患者高磷血症清除的临床研究 被引量:7

Clinical Study of Three Different Modes of Blood Purification for Clearance of Serum Phosphate in Maintenance Hemodialysis Patients
原文传递
导出
摘要 目的观察三种不同血液净化方式[血液透析(HD)、血液透析滤过(HDF)、血液透析+血液灌流(HD+HP)]对维持性血液透析患者高磷血症清除效果。方法选择2009年2月-2011年2月行维持性血液透析的48例高磷血症患者为研究对象,所有患者在低钙透析(1.25 mmol/L)的基础,随机分为HD组、HDF组、HD+HP组,每组16例,分别在治疗时及治疗后4周、8周检查钙、磷、钙磷乘积和全段甲状旁腺激素,并观察其变化。结果在治疗4周、8周后,HDF组、HD+HP组磷较前均显著下降(P值均<0.05),两组同时点相比较差异无统计学意义(P>0.05);HD组较前血磷无明显变化(P>0.05)。结论 HDF、HP清除维持性血液透析患者高磷有显著的效果,而HD效果则不佳。 Objective To study the effect of three different modes of blood purification (HD: hemodialysis, HDF: hemodiafiltration, and HD+HP: hemodialysis and hemoperfusion) for clearance of serum phosphate in maintenance hemodialysis patients. Methods Fourty-eight patients with hyperphosphatemia undergoing maintenance hemodialysis in our department between February 2009 and February 2011 were recruited in our study. They were divided into three groups: HD group, HDF group, and HD+HP group with 16 patients in each. Serum levels of calcium, phosphate, intact parathyroid hormone (iPTH) and calcium-phosphate product were measured and analyzed before and four, eight weeks after the therapy. Results Four and eight weeks after the therapy, concentrations of Ca, Pi, iPTH and Ca^Pi in HI) group did not obviously change (P 〉 0.05), but levels of Pi, iPTH and CaxPi in HDF group and HD+HP group significantly decreased compared with those before therapy (P 〈 0.05, P 〈 0.01), except for Ca (P 〉 0.05). At the same time, difference was not detected between HDF and HD+HP groups (P 〉 0.05). Conclusion HDF and HP can effectively eliminate serum phosphate in maintenance hemodialysis patients, but HD has poor effect.
出处 《华西医学》 CAS 2013年第4期495-498,共4页 West China Medical Journal
关键词 血液透析 血液灌流 血液透析滤过 高磷血症 Hemodialysis Hemodiafiltration Hemoperfusion Hyperphosphatemia
  • 相关文献

参考文献11

二级参考文献39

  • 1Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[J].J Am Soc Nephrol, 2004, 15:2208-2218.
  • 2Itoh N, Ornitz DM. Evolution of the FGF and FGFR gene families[J]. Trends Genet, 2004, 20:563-569.
  • 3Yan X, Yokote H, Jing Let al. Fibroblast growth factor 23 reduces expression of type-IIa Na+/Pi co-transporter by signaling through a receptor function ally distinct from the known FGFRs in opossum kidney cells[J]. Genes Cells, 2005,10:489-502.
  • 4Kazama JJ, Gejyo F, Shigematsu T, et al. Role of circulating fihroblast growth factor 23 in the development of secondary hyperparathyroidism[J]. Ther Apher Dial, 2005, 9:328-330.
  • 5Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease[J].J Am Soc Nephrol, 2004,16: 520-528.
  • 6Forley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of calcium and phosphate metabolism in chronic renal disease [J].Am J Kidney Dis, 1998,32: S112-S119.
  • 7Lindsay RM, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis[J].AmJ Kidney Dis, 2003,42 (Suppl 1): 24-29.
  • 8Hutchison, Alastair J. Improving phosphate-binder therapy, a way forward[J]. Nephrol dial Transplant, 2004,19(Suppl 1): 19-24.
  • 9Bellasi A, Kooienga L, Block GA. Phosphate binders: New products and challenges[J]. Bemodial Intern, 2006, 32: S112- S119.
  • 10EWA Lewin E,Garfia B,Recio FL,et al.Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation.J Am Soc Nephrol,2002,13:2110-2116.

共引文献172

同被引文献36

引证文献7

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部